When was the company founded?

The company was registered in the Polish National Court Register (KRS) on February 18, 2002.

Where is the headquarters located?

The headquarters is located at: 3-Go Maja 52, 08-110 Siedlce.

What is the share capital?

The share capital of the company is PLN 100,000 (approx. $27,012).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

The company reported a revenue of USD 8,875 in 2025, which is an increase of 1.7% compared to 2024.

No, in 2025 the company was not profitable, reporting a net loss of USD 1,423. For comparison, in 2024 the loss was USD 1,959, meaning the company reduced its loss by 27.5%.

Which cost dominates operating expenses?

The largest operating cost category falls under other operating costs. This category amounted to USD 9,220 in 2025, representing 90% of all operating expenses.

Endemedsp. z o.o.

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2002-02-18

Share capital

100,000.00 PLN

Registered address

3-Go Maja 52/4, 08-110 Siedlce, Poland

Website

endemed.pl

Opening hours

Monday–Friday: 8:00–16:00

Financials

Revenue history (in k)

Filing timeliness

1 of 6 financial statements was filed late (for 2025, 48 days late).

202501/09/2026
202429/03/2025
202328/03/2024
202220/06/2023
202128/06/2022
202025/06/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 8.88kMedianUSD 81.65kAverageUSD 795.34k

Net profit

This companyUSD -1.42kMedianUSD 3.31kAverageUSD 31.78k

Operating costs

This companyUSD 10.30kMedianUSD 78.02kAverageUSD 758.75k

Assets

This companyUSD 73.04kMedianUSD 73.04kAverageUSD 113.04k

Industry

Offer

ECG paper
Ultrasound paper
Diagnostic gels
Electrodes
Examination recording systems
Surgical instruments
Electrosurgical equipment

Authorized Representatives

Norbert Paweł Górski – Prezes Firmy

Stanisław Walenty Górski – Attorney-in-fact (sole)

Manner of representation

To make declarations of will and sign on behalf of the company, in the case of a multi-member management board, two members of the management board acting jointly are authorised.

Ownership

Owner	Shares	Share value	Stake
Norbert Paweł Górskiage 59	190	$25,661.80	95%
Others	10	$1,350.62	5%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 1997-07-16.

ING Bank Śląski
36 1050 1894 1000 0023 2642 3148

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Sep 20, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	––	Prezes Zakładu Ubezpieczeń Społecznych
Jun 20, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	––	Prezes Zakładu Ubezpieczeń Społecznych
Apr 28, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	––	Prezes Zakładu Ubezpieczeń Społecznych

Competitors

	Name	Revenue	Website
	Intertransplant Europasp. z o.o.	$22,261.12	intertransplant.com

Change history

Date	Event
2003-02-20	Share capital increase (4,000.00 PLN → 100,000.00 PLN)
2003-02-20	Name change (N & D Medical → Endemed)
2002-02-18	Entered in the register

FAQ

Last updated: 2026-09-01